Abstract
Get full access to this article
View all access options for this article.
References
1.
Astellas
Pharma
.
Astellas celebrates the opening of its new large-scale gene therapy manufacturing facility in North
Carolina
. June 8, 2022. https://newsroom.astellas.us/2022-06-08-Astellas-Celebrates-the-Opening-of-Its-New-Large-Scale-Gene-Therapy-Manufacturing-Facility-in-North-Carolina (last accessed
June 11 , 2022
).
2.REGENXBIO. REGENXBIO opens state-of-the-art gene therapy manufacturing facility. June 9, 2022 . https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-opens-state-art-gene-therapy-manufacturing-facility (last accessed
June 11 , 2022
).
3.
BioMarin
Pharmaceutical
. BioMarin announces durable hemostatic efficacy maintained over 6 years in Ongoing Phase 1/2 Study of valoctocogene roxaparvovec,
investigational gene therapy for hemophilia
A
. https://investors.biomarin.com/2022-05-31-BioMarin-Announces-Durable-Hemostatic-Efficacy-Maintained-Over-6-years-in-Ongoing-Phase-1-2-Study-of-Valoctocogene-Roxaparvovec,-Investigational-Gene-Therapy-for-Hemophilia-A (last accessed
June 11 , 2022
).
4.
Bluebird
Bio
.
FDA Advisory
Committee unanimously supports beti-cel gene therapy for people with beta-thalassemia who require regular red blood cell transfusions
. June 10, 2022. https://investor.bluebirdbio.com/news-releases/news-release-details/fda-advisory-committee-unanimously-supports-beti-cel-gene (last accessed
June 11 , 2022
)
5.
CSL
Behring
.
FDA Accepts CSL Behring's Biologics License
Application for etranacogene dezaparvovec for priority review
. May 24, 2022. https://www.cslbehring.com/newsroom/2022/fda-bla-etranacogene-dezaparvovec (last accessed
June 13 , 2022
).
6.
Vertex Pharmaceuticals and CR
,
ISPR
Therapeutics
.
Vertex and CR
ISPR Therapeutics present new data on more patients with longer follow-up treated with exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress. June 11, 2022. https://investors.vrtx.com/news-releases/news-release-details/vertex-and-crispr-therapeutics-present-new-data-22-patients (last accessed
June 13 , 2022
).
7.
SwanBio Therapeutics. SwanBio Therapeutics announces $56 million series B financing to advance novel gene therapies for neurological conditions. May 18, 2022. https://www.businesswire.com/news/home/20220518005165/en/SwanBio-Therapeutics-Announces-56-Million-Series-B-Financing-to-Advance-Novel-Gene-Therapies-for-Neurological-Conditions (last accessed
June 13 , 2022
).